MA-BLUECONIC
25.1.2024 13:59:34 CET | Business Wire | Press release
Working with market-leading customer data platform (CDP) BlueConic, Dutch telecommunications company VodafoneZiggo has revolutionised its customer engagement strategies, resulting in a 17.6% increase in website interactions and a 4.53% reduction in churn. The collaboration has earned both companies a Platinum award for Best Customer Data Platform Solution in Juniper Research’s Future Digital Awards for Telco Innovation.
Presented by Juniper Research, the awards recognize the most innovative and disruptive telecommunications solutions operating across numerous areas. VodafoneZiggo has already won several awards for its dedication to data-driven decision-making and experimentation but knew it needed to unify its first-party customer data across numerous disparate systems and sources in order to boost engagement, deliver better customer experiences, and ultimately drive customer acquisition and retention. While some CDPs mostly focus on data unification and others tout personalization offerings, VodafoneZiggo is able to do both with BlueConic.
Leveraging the platform to understand customer preferences, easily segment their audiences, and target customers and households across channels with real-time data, VodafoneZiggo was able to transform its customer engagement strategy in several key areas:
- Product recommendations: Using BlueConic, the conversion rate optimization (CRO) team can identify which operating system (OS) a customer is using while browsing their website. Knowing customers are likely to purchase the same type of phone again, they can personalize the shopping experience by only showing them phones with the same OS. For customers using a different OS, product recommendations dynamically update to show recently browsed devices. Within the first six months, this strategy drove a 3.5% increase in clickthrough for returning mobile visitors. On the B2B side of the business, they saw a 2.26% increase on product detail page visits and a 2.95% increase in add-to-carts. For B2C, there was a 17.6% increase in interactions for both new and returning visitors.
- Targeting and personalization: VodafoneZiggo also leverages BlueConic to automatically send segments into custom audiences in Facebook – eliminating the need for manual uploads from their CRM system. Because segments update in real-time, ads are automatically suppressed for customers who have already purchased a new phone or renewed a subscription, thereby optimising their targeting efforts while increasing their return on ad spend (ROAS).
- Churn prevention: By connecting churn probability scores from their Advanced Analytics department to BlueConic profiles, VodafoneZiggo can automatically route at-risk customers to chat with customer support specialists online. This strategy resulted in a 4.53% reduction in churn, a 7.14% increase in chats, and decreased web-to-call by 7.14%.
“While we’re no stranger to winning awards, it’s even more rewarding when we can share that recognition with our customers to celebrate their success,” said Ifoma Smart, VP of Global Customer Success at BlueConic. “When it comes to innovation, technology is just one part of the puzzle. You also need strong processes and a skilled and talented team – attributes VodafoneZiggo has in abundance. They quickly discovered BlueConic not only provides a better way to access and utilize first-party data to drive customer engagement but also offers the flexibility to grow with their business. We’re delighted their success with our customer data platform has been recognized by the esteemed analysts at Juniper Research.”
About Juniper Research
Juniper Research provides research and analytical services to the global hi-tech communications sector; providing consultancy, analyst reports and industry commentary.
About Juniper Research’s Future Digital Awards
Since 2008, the Future Digital Awards have honoured the companies leading innovation and disruption in their respective markets. Winners of the awards are known for developing and implementing groundbreaking products and solutions that have the potential to disrupt their ecosystem, whilst providing substantial benefits to consumers and the wider industry.
About BlueConic
BlueConic, the leading pure-play customer data platform, liberates companies’ first-party data from disparate systems and makes it accessible wherever and whenever it is required to transform customer relationships and drive business growth. Over 350 companies worldwide, including Forbes, Heineken, Mattel, Michelin, Telia Company, and VF Corp, use BlueConic to unify data into persistent, individual- profiles, and then activate it across customer touchpoints and systems in support of a wide range of growth-focused initiatives, including customer lifecycle orchestration, modeling and analytics, digital products and experiences, audience-based monetization, and more. Learn more at www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240125760576/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom